@article{TEXTUAL,
      recid = {5516},
      author = {Derman, Benjamin A. and Chari, Ajai and Zonder, Jeffrey  and Major, Ajay and Stefka, Andrew T. and Jiang, Ken and  Karrison, Theodore and Jasielec, Jagoda and Jakubowiak,  Andrzej},
      title = {A phase I study of selinexor combined with weekly  carfilzomib and dexamethasone in relapsed/refractory  multiple myeloma},
      journal = {European Journal of Haematology},
      address = {2023-02-01},
      number = {TEXTUAL},
      abstract = {We performed a phase I study of weekly selinexor,  carfilzomib, and dexamethasone (wSKd) in patients with  relapsed/refractory multiple myeloma (MM). The primary  objective was to identify the maximum tolerated dose (MTD)  of wSKd. Secondary endpoints included overall response rate  (ORR), progression-free survival (PFS), and overall  survival (OS). Prior exposure/refractoriness to carfilzomib  was permitted. Thirty patients were enrolled; 26 (87%) had  triple-class exposed disease and 6 (20%) received chimeric  antigen receptor (CAR) T-cell therapy. Dose level 2  (carfilzomib 70 mg/m2 Intravenous [IV] on Days 1, 8, and  15; selinexor 100 mg PO on Days 1, 8, 15, 22; dexamethasone  40 mg on Days 1, 8, 15, 22 of 28-day cycles) was chosen as  the MTD, with no DLTs having occurred. The most common  hematologic adverse events (AE) were thrombocytopenia  (83%), anemia (70%), lymphopenia (50%), and neutropenia  (50%). The most common nonhematologic AE were fatigue  (70%), nausea (70%), diarrhea (53%), and anorexia (47%).  The ORR was 21/30 (70%) overall and 18/23 (78%) at the MTD.  At a median follow-up of 12.3 months, the median PFS was  5.3 months and median OS 23.3 months. Responses were  similar in carfilzomib naïve and exposed patients.  Long-term efficacy of wSKd is modest; wSKd could be  employed as a bridging strategy to immunotherapies.},
      url = {http://knowledge.uchicago.edu/record/5516},
}